Read More

Axcella Announced Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical tria

AXLA